HOME >> BIOLOGY >> NEWS
Penn researchers determine structure of binding site of colon-cancer drug and its protein target

(Philadelphia, PA) Researchers at the University of Pennsylvania School of Medicine have determined the precise molecular details of how Erbitux, a recently approved colorectal cancer drug, binds to its target on cancer cells. Knowing this chemical configuration will lead to better drug design for this family of cancer medications.

Colorectal cancer is one of the most frequently diagnosed cancers in men and women, as well as the second-leading cause of cancer-related death, according to the Centers for Disease Control and Prevention. Erbitux works by binding to a protein on the surface of cancer cells, thereby halting excessive cell growth that leads to tumors. Kate Ferguson, PhD, Assistant Professor of Physiology, and colleagues, describe their findings in the April cover article of Cancer Cell.

"By having determined the structure of Erbitux bound to its cellular target receptor, we get new insight into how the drug blocks the receptor's cell growth-promoting activities, and can use this to guide future drug design," says Ferguson.

As is characteristic of many epithelial cancers such as cancers of the head and neck, breast, ovary, lung, and pancreas the surface of cancer cells possess abnormally high levels of epidermal growth factor receptor (EGFR), the protein that interacts with Erbitux. These receptors are made up of three parts: one outside the cell; another passing through the cell membrane; and the third inside the cell. In a cancer cell, an extracellular hormone binds to the outer piece of EGFR, and causes the inside part to kick off a series of reactions that signal the cancerous cell to replicate and divide.

Ferguson and colleagues determined that Erbitux works to halt cell proliferation by blocking EGFR's molecular doorway, disallowing hormones to bind and signal tumor growth. X-ray crystallography provided a snapshot of the interaction between Erbitux and the extracellular component of the cancer cell's receptors. '"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
18-Apr-2005


Page: 1 2

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. Penn researchers discover how key protein stops inflammation
3. ASU researchers partner with UOP to make biofuel for military jets a reality
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. U-M researchers find family of on switches that cause prostate cancer
7. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. MGH researchers confirm that bone marrow restores fertility in female mice
10. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
11. U-M researchers identify gene involved in breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/5/2020)... ... June 04, 2020 , ... Greffex, a pioneering vaccine and ... of Directors. , “Neil understands the need for a global perspective to make an ... of Greffex. Mr. Bush will serve as an independent, director of the company. , ...
(Date:5/28/2020)... ... May 27, 2020 , ... Today bioinformatics leader hc1® ... uniquely combines lab testing insights and hc1’s exclusive Local Risk Index in a ... safety of employees returning to the workplace. , “Some of the best ways ...
(Date:5/25/2020)... ... May 22, 2020 , ... Oxford Nanopore Technologies is in advanced development of ... that causes COVID-19. , The LamPORE assay is designed to be rapid, ... very large numbers of samples. Hardware and reagents sit outside current, squeezed supply ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World has announced ... Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the ... awards program, highlighting outstanding examples of how technology innovations and strategic initiatives can ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... insights, today announced that the launch of a new clinical diagnostics ... about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... cancer, today announced the company has entered a license agreement with Roswell Park ... Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... complex indoor environments, announced today that Derek Fournier has been appointed CEO and ... of the Board, effective immediately. , “DeCurtis Corporation has been on an ...
Breaking Biology Technology:
Cached News: